High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study—TROG 96:07
- 1 December 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (23) , 4371-4376
- https://doi.org/10.1200/jco.2003.03.154
Abstract
Purpose: The effectiveness of synchronous carboplatin, etoposide, and radiation therapy was prospectively assessed in a group of patients with high-risk Merkel cell carcinoma (MCC) of the skin. Patients and Methods: Patients were eligible if they had disease localized to the primary site and nodes, and were required to have at least one of the following high risk features: recurrence after initial therapy, involved nodes, primary tumor size greater than 1 cm, gross residual disease after surgery, or occult primary with nodes. Radiation was delivered to the primary site and nodes to a dose of 50 Gy in 25 fractions over 5 weeks and synchronous carboplatin (area under the curve, 4.5) and intravenous etoposide 80 mg/m2 days 1 to 3 was given in weeks 1, 4, 7, and 10. The median age of the group was 67 (range, 43–86) years, and there were 39 males and 14 females. Involved nodes (stage II) were present in 33 cases (62%). The sites involved were head and neck (22 patients), occult primary (13 patients), upper limb (eight patients), lower limb (eight patients), and trunk (two patients). Results: Fifty-three patients were entered between 1996 and 2001. The median potential follow-up was 48 months. There were no treatment related deaths. The 3-year overall survival, locoregional control, and distant control were 76%, 75%, and 76%, respectively. Tumor site and the presence of nodes were factors that were predictive for local control and survival. Multivariate analysis indicated that the major factor influencing survival was the presence of nodes; however, this was not a significant factor in locoregional control. Conclusion: High levels of locoregional control and survival have been achieved with the addition of chemotherapy to radiation treatment for high-risk MCC of the skin. The role of chemoradiotherapy for high-risk MCC warrants further investigation.Keywords
This publication has 17 references indexed in Scilit:
- Analysis of toxicity of Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group studyInternational Journal of Radiation Oncology*Biology*Physics, 2001
- The natural history and management of Merkel cell carcinoma of the skin: A review of 22 patients treated at the Royal Marsden HospitalClinical Oncology, 1997
- Early aggressive treatment for Merkel cell carcinoma improves outcomeThe American Journal of Surgery, 1997
- The role of radiation therapy and chemotherapy in the treatment of merkel cell carcinomaCancer, 1997
- The importance of postoperative radiation therapy in the treatment of Merkel cell carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Further insights into the natural history and management of primary cutaneous neuroendocrine (Merkel cell) carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Merkel Cell CarcinomaArchives of Surgery, 1991
- Merkel cell tumour: Clinical behaviour and treatmentBritish Journal of Surgery, 1991
- The essential role of radiation therapy in securing locoregional control of merkel cell carcinomaPublished by Elsevier ,1990
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989